Bariatric surgery: effects on glucose homeostasis

被引:78
作者
Rubino, Francesco
机构
[1] IRCAD EITS, European Inst Telesurg, F-67091 Strasbourg, France
[2] Catholic Univ, Dept Surg, Rome, Italy
关键词
biliopancreatic diversion; diabetes; duodenal-jejunal bypass; gastric bypass; insulin resistance; obesity surgery;
D O I
10.1097/01.mco.0000232914.14978.c5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review This article provides an overview of the effect of bariatric surgery on type 2 diabetes. It focuses on current hypotheses about the mechanism of diabetes control after Roux-en-Y gastric bypass surgery, and discusses the relationship between gastrointestinal anatomy and glucose homeostasis. Recent findings Along with sustained body weight loss, all bariatric operations lead to improvement or resolution of comorbid disease states, particularly type 2 diabetes. Roux-en-Y gastric bypass and biliopancreatic diversion are the most effective methods to control diabetes, resulting in persistent normal concentrations of plasma glucose, insulin, and glycosylated haemoglobin in 80-100% of cases. Resolution of diabetes after such treatment typically occurs too fast to be accounted for by weight loss alone. Recent animal investigations using duodenal-jejunal bypass, a stomach-preserving experimental model of Roux-en-Y gastric bypass, have shown that diabetes control is not a mere collateral effect of the treatment of obesity, but directly results from the exclusion of the duodenum and proximal jejunum from the flow of nutrients. Summary Results from clinical series and animal studies suggest that type 2 diabetes is a potentially operable disease. This indicates the need for carefully conducted clinical trials to define the ideal-candidate patients and the most suitable type of operation for surgical treatment of type 2 diabetes. Understanding the exact mechanism by which Roux-en-Y gastric bypass controls diabetes is a priority because such knowledge may help us to understand the relationship between gastrointestinal physiology and insulin resistance as well as to help us identify new targets for novel antidiabetic medications.
引用
收藏
页码:497 / 507
页数:11
相关论文
共 61 条
  • [1] BITTNER R, 1981, Z GASTROENTEROL, V19, P698
  • [2] Malabsorptive gastric bypass in patients with superobesity
    Brolin, RE
    LaMarca, LB
    Kenler, HA
    Cody, RP
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2002, 6 (02) : 195 - 203
  • [3] Bariatric surgery: A systematic review and meta-analysis
    Buchwald, H
    Avidor, Y
    Braunwald, E
    Jensen, MD
    Pories, W
    Fahrbach, K
    Schoelles, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (14): : 1724 - 1737
  • [4] Interactions between insulin resistance and insulin secretion in the development of glucose intolerance
    Cavaghan, MK
    Ehrmann, DA
    Polonsky, KS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (03) : 329 - 333
  • [5] Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery
    Cowan, GSM
    Buffington, CK
    [J]. WORLD JOURNAL OF SURGERY, 1998, 22 (09) : 987 - 992
  • [6] Gastric bypass for obesity: Mechanisms of weight loss and diabetes resolution
    Cummings, DE
    Overduin, J
    Foster-Schubert, KE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) : 2608 - 2615
  • [7] Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.
    Cummings, DE
    Weigle, DS
    Frayo, RS
    Breen, PA
    Ma, MK
    Dellinger, EP
    Purnell, JQ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) : 1623 - 1630
  • [8] Pharmacologic therapy for type 2 diabetes mellitus
    DeFronzo, RA
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) : 281 - 303
  • [9] Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity
    DeMaria, J
    Sugerman, HJ
    Kellum, JM
    Meador, JG
    Wolfe, LG
    [J]. ANNALS OF SURGERY, 2002, 235 (05) : 640 - 645
  • [10] Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus
    Evans, A
    Krentz, AJ
    [J]. DRUG SAFETY, 1999, 21 (01) : 7 - 22